Phase I clinical trial of lobaplatin combined with image-guided volume-modulated arc radiation therapy in locally advanced cervical cancer Authors: Jing You, Danning Wu, Jian Tie, Junyue Shen, Yidi Yuan, Xiaoxuan Gu, Weihu Wang, Xiaofan Li Published: 2026 ABSTRACT BackgroundWe aimed to determine the maximum tolerable dose (MTD) and dose-limiting toxicities (DLTs) of weekly lobaplatin chemotherapy concurrent with external beam radiotherapy (EBRT) using image-guided volumetric-modulated arc therapy (VMAT) and brachytherapy in locally advanced cervical cancer (LACC).MethodsPatients with clinical stage IB3-IVA cervical cancer were enrolled following a standard 3 + 3 dose escalation design. Patients received EBRT with 45 Gy in 25 fractions to the pelvis and 60 Gy in 25 fractions to the involved lymph nodes. Then high-dose-rate intracavitary brachytherapy was conducted with 28 Gy in 4 fractions. The starting dose of weekly lobaplatin was 8 mg/m2, then increased by 2 mg/m2 for a total of 5 levels. The primary endpoints were the MTD and DLTs of weekly lobaplatin. DLTs were defined as follows: 1) grade 4 neutropenia, or thrombocytopenia of grade 3 or higher; 2) grade 3 or higher nonhematologic toxicity; and 3) failure to complete 3 cycles of lobaplatin due to treatment-related toxicity.ResultsBetween December 2020 and October 2022, 21 patients were enrolled. Three patients experienced DLTs: grade 3 fatigue at 14 mg/m2, receiving two cycles of chemotherapy at 16 mg/m2, and grade 3 fatigue at 16 mg/m2. The only severe and dose-limiting nonhematologic toxicity was grade 3 fatigue. The MTD of weekly lobaplatin was 14 mg/m2.ConclusionsThe MTD of weekly lobaplatin concurrent with VMAT and brachytherapy for LACC was established as 14 mg/m2. A weekly dose of 12 mg/m2 of lobaplatin is recommended in combination with radiotherapy in patients with LACC.Trial registrationThis study is registered with chictr.org, ChiCTR2000040113 on 21 November 2020 prior to participant enrollment, and is now complete.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12885-026-16089-w. Introduction Cervical cancer has the highest prevalence of gynecological tumors and presents as a locally advanced stage at the time of diagnosis in approximately 70% of patients [1]. For locally advanced cervical carcinoma (LACC), the current standard treatment regimen is radiotherapy with concurrent platinum-based chemotherapy [1–3]. Compared with conventional radiation therapy, intensity-modulated radiation therapy, especially image-guided volumetric-modulated arc therapy (VMAT), can reduce radiation-related late toxicity [4, 5]. Cisplatin is the most commonly used regimen for cervical carcinoma concurrent chemoradiotherapy (CCRT). Cisplatin-containing CCRT has been shown to reduce the recurrence risk by 40–60% compared to that of radiotherapy alone [3]. However, the high gastrointestinal toxicity, nephrotoxicity, ototoxicity, and neurotoxicity profile of cisplatin is intolerable to some patients. Carboplatin is an alternative option for patients who are not receiving cisplatin due to its lower renal, neurological and gastrointestinal toxicity; nonetheless, it has been reported to have more severe hematologic toxicity than cisplatin [6, 7]. Therefore, further investigation of the different chemotherapy regimens with concurrent radiotherapy is warranted. Lobaplatin is a third-generation platinum anticancer drug that has mild gastrointestinal toxicity, nephrotoxicity, ototoxicity, neurotoxicity and has no complete cross-resistance with cisplatin [8, 9]. Previous studies have shown the broad-spectrum anticancer effects of lobaplatin, including its efficacy against esophageal cancer, ovarian cancer, breast cancer, head and neck cancer, and lung cancer [10, 11]. Several studies have shown that lobaplatin has short-term efficacy [12] and long-term survival outcomes similar to cisplatin [13, 14]. Lobaplatin is generally administered at doses of 30–50 mg/m2 every 3–4 weeks, with 50 mg/m2 for single-agent chemotherapy and 30 mg/m2 for combination therapies in China based on previous studies [14, 15]. Gietama et al. revealed that the dose-limiting toxicity (DLT) of continuous infusion of lobaplatin for 72 h was thrombocytopenia, and a dose of 45 mg/m2/72 h was recommended for every 4 weeks in a future phase II study [16]. Similarly, another phase I study reported that thrombocytopenia was the dose-limiting toxicity of lobaplatin (given intravenously every 3–4 weeks) and recommended a dose of 50 mg/m2/3–4 weeks for single-agent therapy [17]. However, the DLT and maximum tolerable dose (MTD) of lobaplatin when given weekly concurrently with radiotherapy in patients with cervical cancer have not been well studied. This exploratory phase I trial aimed to determine the optimal dose of weekly lobaplatin concurrently with radiotherapy and evaluate its safety and efficacy profile in patients with LACC. Materials and methods Study design This single-arm, prospective phase I trial was conducted at Peking University Cancer Hospital. The trial used a standard 3 + 3 dose escalation design (Fig. 1). Lobaplatin chemotherapy weekly dose was administered from 8 mg/m2 concurrently with radiotherapy. First, three patients with locally advanced cervical cancer were included into the first cohort (weekly lobaplatin chemotherapy at 8 mg/m2 concurrent with radiotherapy). Patients received all planned cycles at their assigned dose level. If none of the three patients experienced DLT, the dose was escalated to the next level. If DLT occurred in one patient at any cohort, an additional three patients were included into the same cohort. If DLT did not occur in any of the other three patients, the dose was increased. If DLTs occurred in any patient at the same cohort, the trial was stopped, and the MTD was determined to be the previous dose level. If a DLT occurred in two or more patients at any cohort, the trial was stopped. The MTD was determined to be the previous dose if two or more DLTs occurred at any cohort. DLTs were defined as follows: 1) grade 4 neutropenia, or grade 3 or higher thrombocytopenia; 2) grade 3 or higher nonhematologic toxicity (except nausea, vomiting, or alopecia); and 3) less than 3 cycles of lobaplatin due to hematologic or nonhematologic toxicity.Fig. 1Dose escalation of weekly lobaplatin chemotherapy concurrent with radiotherapy in patients with locally advanced cervical cancer Dose escalation of weekly lobaplatin chemotherapy concurrent with radiotherapy in patients with locally advanced cervical cancer This clinical trial was reported in accordance with the CONSORT (Consolidated Standards of Reporting Trials) extension for phase I trials. Patients Eligible patients were consecutively enrolled from the radiation oncology outpatient clinic between December 2020 to October 2022. Patient recruitment and consenting took place within the clinical setting. Data for the study were collected from multiple sources: radiotherapy parameters were retrieved from the departmental Oncology Information System; imaging data were obtained from the Picture Archiving and Communication System of the Department of Radiology; and patient-reported outcomes and survival follow-up were managed by the institutional clinical research coordinator. The main eligibility criteria include: 1) age between 18 and 75 years old; 2) pathologically confirmed cervical carcinoma; 3) clinical stage of IB3-IVA (according to FIGO 2018); 4) without previous anticancer therapy against cervical carcinoma; 5) Eastern Cooperative Oncology Group (ECOG) performance status 0–1; 6) documentation of adequate marrow function (white blood cells ≥ 4 × 109/L; neutrophils ≥ 2.0 × 109/L; platelet count ≥ 100 × 109/L; hemoglobin ≥ 80 g/L), normal hepatic and renal function (total bilirubin < 1.5 × upper limit of normal (ULN); alanine aminopeptidase and aspartate aminotransferase ≤ 1.5 × ULN; serum creatinine ≤ ULN; creatinine clearance rate ≥ 60 ml/min (according to Cockcroft-Gault equation), international normalized ratio of prothrombin time (INR) ≤ 1.5 × ULN and normal electrocardiograph; and 7) signed informed consent form. The main ineligibility criteria included 1) known allergy to lobaplatin; 2) intolerance to concurrent chemoradiotherapy; 3) other malignancy experienced within the previous 5 years, except for adequately treated carcinoma in situ of the cervix and basal or squamous skin cancer; 4) poorly controlled medical conditions or major surgery history within 4 weeks prior to enrollment; and 5) participation in a clinical trial of any investigational drugs within 4 weeks prior to the current study. Radiotherapy Cone-beam computed tomography (CBCT) was conducted daily before the first three treatments and then once a week thereafter. External beam radiotherapy (EBRT) was delivered five days per week with mega-voltage equipment (≥ 6 MV) using VMAT. Computed tomography (CT) was performed while the patients were in the supine position, had a full bladder, and an empty rectum. The gross tumor volume (GTVnd) of the metastatic lymph nodes included any suspected metastatic lymph nodes within the regional lymph node area based on diagnostic and simulation imaging. The clinical target volume (CTV) included gross tumor, uterus, cervix, vagina according to the involvement, parametrial and paravaginal tissues, ovaries, and lymphatic drainage areas, including pelvic lymph nodes and/or para-aortic area. The planning target volume margins were 0.5 cm beyond the CTV. A dose of 60 Gy in 25 fractions was prescribed for the planning GTV of the metastatic nodes (PGTVnd), while a dose of 45 Gy in 25 fractions was prescribed for the planning target volume (PTV). The dose restrictions for the organs at risk (OARs) were as follows: rectum, V30 ≤ 50%; D2 cc ≤ 65–75 Gy; bladder, V50 ≤ 5%; V35 ≤ 50%; femoral head, V50 ≤ 5%; spinal cord, Dmax ≤ 45 Gy; small intestine, V15 ≤ 120 cc; and kidneys, V20 < 32%, mean kidney dose < 15–18 Gy. High-dose-rate (HDR) intracavitary brachytherapy using 192Ir was performed in all patients after 15 to 20 fractions of EBRT. Intracavity brachytherapy was performed with an image-guided high-dose rate once per week with 28 Gy in 4 fractions to the Manchester A point. Chemotherapy Patients received the single agent lobaplatin as concurrent chemotherapy. Lobaplatin was administered weekly for six cycles, starting on the first day of radiotherapy. Standard antiemetic medication (5-hydroxytryptamine 3 receptor antagonist) was given. Dose adjustments The administration of radiotherapy and lobaplatin was guided by specific toxicity criteria. Radiotherapy would be suspended and lobaplatin was to be delayed in cases of grade 4 neutropenia or grade 3 or higher thrombocytopenia, with a corresponding reduction to the previous level in the lobaplatin dose. Lobaplatin was to be delayed if the patient presented with a leukocyte count < 3.0 × 109/L, grade 2 or higher neutropenia, or a platelet count < 90 × 109/L. If grade 3 non-hematological toxicity (except nausea, vomiting and alopecia) occurred, the dose of lobaplatin would be reduced to the previous level. Outcome measures The primary endpoints were the MTD and DLT of weekly lobaplatin combined with VMAT. Acute treatment-related toxicities were assessed using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Acute and late radiation toxicities were assessed according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) radiation toxicity scale. Tumor response was evaluated using pelvic MRI. according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1). For time-to-event endpoints, such as PFS, OS and median follow-up, were estimated using the Kaplan–Meier method. Continuous variables were described by mean or median, as well as the minimum and maximum values. Discrete variables were presented as frequencies and percentages. All statistical analyses were conducted with IBM SPSS Statistics (v27.0) and R software (v4.5.1). Results Patient characteristics From December 2020 to October 2022, 21 patients were enrolled in the current study. The baseline and treatment characteristics of the patients are listed in Table 1. All patients had squamous cell carcinoma. All patients completed EBRT and brachytherapy per protocol. Seventeen patients (81.0%) received pelvic EBRT, and 4 patients (19.0%) received pelvic and para-aortic EBRT. Eighteen patients (85.7%) received simultaneous boost to the suspected lymph nodes. In terms of brachytherapy, all patients except one received brachytherapy with 28 Gy in 4 fractions. The median overall treatment time was 47 days (range: 36–72 days).Table 1Baseline and treatment characteristicsPatients (n = 21)Age, years57 (32–68)ECOG performance status score 011 (52.4%) 110 (47.6%)Pathological type Squamous cell carcinoma21 (100%) Adenocarcinoma or adenosquamous carcinoma0 (0%)2018 FIGO stage IB32 (9.6%) IIA14 (19.0%) IIB7 (33.3%) IIIB2 (9.5%) IIIC16 (28.6%)Completion of radiotherapy Yes21 (100%) No0 (0%)Chemotherapy cycles 66 (28.6%) 55 (23.8%) 46 (28.6%) 33 (14.2%) 21 (4.8%)Overall treatment time, day47 (36–72)FIGO the international federation of gynecology and obstetrics Table 1Baseline and treatment characteristicsPatients (n = 21)Age, years57 (32–68)ECOG performance status score 011 (52.4%) 110 (47.6%)Pathological type Squamous cell carcinoma21 (100%) Adenocarcinoma or adenosquamous carcinoma0 (0%)2018 FIGO stage IB32 (9.6%) IIA14 (19.0%) IIB7 (33.3%) IIIB2 (9.5%) IIIC16 (28.6%)Completion of radiotherapy Yes21 (100%) No0 (0%)Chemotherapy cycles 66 (28.6%) 55 (23.8%) 46 (28.6%) 33 (14.2%) 21 (4.8%)Overall treatment time, day47 (36–72)FIGO the international federation of gynecology and obstetrics Baseline and treatment characteristics FIGO the international federation of gynecology and obstetrics DLT Five concurrent weekly lobaplatin doses were investigated, with 3, 3, 3, 6 and 6 patients assigned to dose levels of 8 mg/m2, 10 mg/m2, 12 mg/m2, 14 mg/m2, and 16 mg/m2, respectively (Fig. 2). The individual dose adjustment patterns for the patients are shown in Fig. 3. Three patients experienced DLT events. At level 4, one patient had grade 3 fatigue, resulting in three additional patients being assigned to this level. There was no DLT in the three additive patients at level 4. In the first three patients in level 5, one patient received two cycles of weekly lobaplatin due to fatigue or myelosuppression, and one patient experienced grade 3 fatigue in the additional three patients in level 5. At dose levels 1–3, all but one patient received 5–6 cycles of weekly lobaplatin, and one patient received 4 cycles with no severe toxicity recorded. At levels 4–5, however, only three patients (25%) received 5–6 cycles of concurrent chemotherapy. Patients at levels 1–4 received the complete lobaplatin regimen, with a median number of four or more chemotherapy cycles. Thus, the MTD for concurrent weekly lobaplatin was defined as 14 mg/m2/week.Fig. 2Details of lobaplatin dose escalation concurrent with radiotherapy in patients with locally advanced cervical cancerFig. 3Individual dose adjustment patterns for patients with locally advanced cervical cancer Details of lobaplatin dose escalation concurrent with radiotherapy in patients with locally advanced cervical cancer Individual dose adjustment patterns for patients with locally advanced cervical cancer The acute hematologic toxicities were mild overall (Table 2). No grade 4 hematologic toxicities or febrile neutropenia were observed. Grade 3 leukopenia and neutropenia were observed in 7 (33.3%) and 1 (4.8%) patient, respectively. No grade 3 anemia or thrombocytopenia was recorded.Table 2Treatment related acute toxicities according to CTCAE 5.0 and RTOG/EORTC radiation toxicity scaleToxicitiesgradeLobaplatin dose8 mg/m2 (n = 3)10 mg/m2 (n = 3)12 mg/m2 (n = 3)14 mg/m2 (n = 6)16 mg/m2 (n = 6)Leukopenia13 (100%)3 (100%)1 (33.3%)002002 (66.7%)3 (50.0%)2 (33.3%)30003 (50.0%)4 (66.7%)Neutropenia1002 (66.7%)3 (50.0%)020003 (50.0%)5 (83.3%)300001 (16.7%)Anemia10003 (50.0%)1 (16.7%)20001 (16.7%)0Thrombocytopenia10001 (16.7%)3 (50.0%)20001 (16.7%)1 (16.7%)Hepatotoxicity10001 (16.7%)3 (50.0%)2001 (33.3%)1 (16.7%)0300001 (16.7%)Fatigue12 (66.7%)2 (66.7%)1 (33.3%)1 (16.7%)4 (66.7%)200001 (16.7%)30001 (16.7%)1 (16.7%)Nausea12 (66.7%)2 (66.7%)2 (66.7%)4 (66.7%)2 (33.3%)200003 (50.0%)Vomiting100001 (16.7%)Enteritis12 (66.7%)3 (100%)3 (100%)4 (66.7%)3 (50.0%)20002 (33.3%)1 (16.7%)Cystitis101 (33.3%)02 (33.3%)3 (50.0%)20001 (16.7%)0Skin and mucosa13 (100%)3 (100%)3 (100%)3 (50.0%)6 (100%)20001 (16.7%)0Peripheral neuropathy000001 (16.7%)CTCAE Common Terminology Criteria for Adverse Events, RTOG/EORTC Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer Table 2Treatment related acute toxicities according to CTCAE 5.0 and RTOG/EORTC radiation toxicity scaleToxicitiesgradeLobaplatin dose8 mg/m2 (n = 3)10 mg/m2 (n = 3)12 mg/m2 (n = 3)14 mg/m2 (n = 6)16 mg/m2 (n = 6)Leukopenia13 (100%)3 (100%)1 (33.3%)002002 (66.7%)3 (50.0%)2 (33.3%)30003 (50.0%)4 (66.7%)Neutropenia1002 (66.7%)3 (50.0%)020003 (50.0%)5 (83.3%)300001 (16.7%)Anemia10003 (50.0%)1 (16.7%)20001 (16.7%)0Thrombocytopenia10001 (16.7%)3 (50.0%)20001 (16.7%)1 (16.7%)Hepatotoxicity10001 (16.7%)3 (50.0%)2001 (33.3%)1 (16.7%)0300001 (16.7%)Fatigue12 (66.7%)2 (66.7%)1 (33.3%)1 (16.7%)4 (66.7%)200001 (16.7%)30001 (16.7%)1 (16.7%)Nausea12 (66.7%)2 (66.7%)2 (66.7%)4 (66.7%)2 (33.3%)200003 (50.0%)Vomiting100001 (16.7%)Enteritis12 (66.7%)3 (100%)3 (100%)4 (66.7%)3 (50.0%)20002 (33.3%)1 (16.7%)Cystitis101 (33.3%)02 (33.3%)3 (50.0%)20001 (16.7%)0Skin and mucosa13 (100%)3 (100%)3 (100%)3 (50.0%)6 (100%)20001 (16.7%)0Peripheral neuropathy000001 (16.7%)CTCAE Common Terminology Criteria for Adverse Events, RTOG/EORTC Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer Treatment related acute toxicities according to CTCAE 5.0 and RTOG/EORTC radiation toxicity scale CTCAE Common Terminology Criteria for Adverse Events, RTOG/EORTC Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer No grade 4 or higher nonhematologic toxicities were observed (Table 2). Grade 1–2 enteritis and cystitis were the most common adverse events, followed by nausea and fatigue. Grade 3 fatigue was the only severe and dose-limiting nonhematologic toxicity in the present study occurring in one patient at level 4 and one patient at level 5. Table 3 showed the mild late hematologic toxicities in patients. No grade 3 or higher hematological toxicities were observed. Eight patients experienced grade 2 leukopenia, while six and three patients developed grade 1 leukopenia and grade 1 neutropenia, respectively. One case of grade 1 anemia was reported and no patients experienced thrombocytopenia. Among those with acute leukopenia, the median time to recovery was 8 (range, 4–15) months. No grade 2 or higher nonhematologic toxicities were observed. Grade 1 enteritis and fatigue were each reported in three and three patients. The median time to symptom resolution for fatigue was 5 (range, 4–6) months.Table 3Treatment related late toxicities according to CTCAE 5.0 and RTOG/EORTC radiation toxicity scaleToxicitiesgradeLobaplatin dose8 mg/m2 (n = 3)10 mg/m2 (n = 3)12 mg/m2 (n = 3)14 mg/m2 (n = 6)16 mg/m2 (n = 6)Leukopenia12 (66.7%)01 (33.3%)3 (50.0%)02002 (66.7%)2 (33.3%)4 (66.7%)Neutropenia10002 (33.3%)1 (16.7%)Anemia10001 (16.7%)0Thrombocytopenia100000Hepatotoxicity10002 (33.3%)0Fatigue1001 (33.3%)02 (33.3%)Enteritis10002 (33.3%)1 (16.7%)Cystitis100001 (16.7%)CTCAE Common Terminology Criteria for Adverse Events, RTOG/EORTC Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer Table 3Treatment related late toxicities according to CTCAE 5.0 and RTOG/EORTC radiation toxicity scaleToxicitiesgradeLobaplatin dose8 mg/m2 (n = 3)10 mg/m2 (n = 3)12 mg/m2 (n = 3)14 mg/m2 (n = 6)16 mg/m2 (n = 6)Leukopenia12 (66.7%)01 (33.3%)3 (50.0%)02002 (66.7%)2 (33.3%)4 (66.7%)Neutropenia10002 (33.3%)1 (16.7%)Anemia10001 (16.7%)0Thrombocytopenia100000Hepatotoxicity10002 (33.3%)0Fatigue1001 (33.3%)02 (33.3%)Enteritis10002 (33.3%)1 (16.7%)Cystitis100001 (16.7%)CTCAE Common Terminology Criteria for Adverse Events, RTOG/EORTC Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer Treatment related late toxicities according to CTCAE 5.0 and RTOG/EORTC radiation toxicity scale CTCAE Common Terminology Criteria for Adverse Events, RTOG/EORTC Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer Efficacy Twenty patients (95.2%) achieved complete response (CR) and the objective response rate was 95.2%. Recurrence in the cervix occurred 15 months after completion of radiotherapy in one patient, probably due to insufficient brachytherapy dose to the cervix. As of data cut-off, at a median follow-up of 44.2 months (range, 26.7–55.6 months), the 2- and 3-year overall survival (OS) rates were both 100%, while the 2- and 3-year progression-free survival (PFS) rates were 95.2% (95% CI, 86.6–100%) at both time points. One patient was lost to follow-up at 26 months. Discussion This study was designed to determine the MTD of weekly lobaplatin in patients with LACC treated with CCRT. In patients with locally advanced cervical cancer receiving concurrent weekly cisplatin, completing 5–6 cycles was generally considered a complete regimen. Recent studies specifically defined patients who received less than 5 cycles as the "incomplete" cohort and those who received 5–6 cycles as the "complete" cohort. Importantly, it was demonstrated that receipt of incomplete cisplatin was significantly associated with worse oncologic outcomes [18, 19]. Given that DLTs were observed at the 14 mg/m2 dose level, coupled with lower rate of treatment cycle completion and more frequent interruptions, the recommended dose for subsequent phase II/III studies is 12 mg/m2 of weekly lobaplatin administered concurrently with radiotherapy. The primary DLTs observed included fatigue and hematologic events. Overall, both hematologic and nonhematologic treatment-related toxicities were mild. No grade 4 or higher toxicities were observed. The most common toxicities included hematologic toxicities—leukopenia (100%) and neutropenia (61.9%) and nonhematologic toxicities—enteritis (85.7%) and cystitis (33.3%). The only severe nonhematologic toxicity occurred in this study was grade 3 fatigue. There was no evidence of nephrotoxicity or peripheral neuropathy related to lobaplatin. Patients with acute leukopenia returned to normal after 8 months and no grade 3 or higher hematological toxicities were observed. For those with fatigue, symptoms resolved after 5 months. Furthermore, encouraging CR rate and survival outcomes were achieved. Cisplatin, the most common chemotherapeutic agent used in CCRT for cervical carcinoma, is well-known for causing gastrointestinal, renal and neural toxicities. The ACTLACC trial reported a 10% incidence of grade 3–4 myelosuppression and 3% for gastrointestinal adverse effects in patients with LACC receiving CCRT with weekly cisplatin [20]. Therefore, in patients with LACC, it is advantageous to seek alternative chemotherapy agents that are not only effective but also less toxic and more convenient than cisplatin. Several studies have shown that, similar to cisplatin, lobaplatin has been shown in several studies to have comparable short-term efficacy [12] and survival outcomes [13, 14]. Additionally, lobaplatin has a more favorable toxicity profile compared with cisplatin. A phase III randomized controlled study in nasopharyngeal carcinoma showed that induction lobaplatin based chemotherapy followed by concurrent chemotherapy with lobaplatin was associated with a significantly lower incidence of toxicity than cisplatin-based induction chemotherapy followed by concurrent chemotherapy with cisplatin. The reduction was particularly evident in gastrointestinal adverse events, weight loss, nephrotoxicity and long-term neurotoxicity. Hematologic toxicity did not differ significantly between groups [13]. A multicenter retrospective study of postoperative adjuvant chemotherapy for esophageal cancer revealed that patients treated with lobaplatin (50 mg/m2) + docetaxel experienced fewer hematologic, gastrointestinal, and renal toxicities than patients treated with cisplatin combined with docetaxel [14]. In accordance with the findings of previous studies, we observed mild nonhematologic toxicity, namely nausea, vomiting, nephrotoxicity and neurotoxicity. Enteritis and cystitis were more associated with radiation than with lobaplatin administration in this study. The hematologic toxicities were mild overall, particularly in level 1–3. There was no grade 3 or higher myelosuppression in level 1–3, but more than half of the patients in level 4–5 had grade 3 leukopenia. The use of lobaplatin in cervical cancer patients is currently limited. In a randomized controlled trial published in 2015, sixty-one patients with stage II-III cervical cancer were randomly assigned to one of three treatment regimens: cisplatin at 15 mg/m2 per week, cisplatin at 20 mg/m2 per week, or lobaplatin at 35 mg/m2 every three weeks. EBRT and high-dose-rate brachytherapy were administered to all patients. The short-term efficacy and grade 3–4 gastrointestinal toxicities were comparable among the groups. However, patients in the lobaplatin group experienced significantly more grade 3–4 hematological toxicities than those in the cisplatin groups: the rates of grade 3–4 neutropenia were 57.89%, 14.29%, and 23.81%, respectively (P = 0.008); the rates of grade 3–4 thrombocytopenia were 31.58%, 0% and 0%, respectively (P = 0.001). The rates of grade 3–4 gastrointestinal events were 5.26%, 9.52% and 4.76%, respectively, with no significant difference [12]. Although the lobaplatin group exhibited significantly greater hematologic toxicity than the cisplatin groups, it should be noted that the cisplatin dose in the study was lower than the recommended 40 mg/m2 per week. Moreover, data for the entire population (180 patients to be enrolled) have not yet been reported. A retrospective analysis of 120 patients with LACC compared two concurrent chemoradiotherapy regimens and demonstrated no significant difference in 5-year overall survival. The lobaplatin based group (neoadjuvant: paclitaxel 30mg/m2 and lobaplatin 30 mg/m2 every three weeks; concurrent: lobaplatin 30 mg/m2 per week) had comparable outcomes with the cisplatin based group ( neoadjuvant: paclitaxel/cisplatin; concurrent: cisplatin 40 mg/m2 per week) [21]. The incidence of gastrointestinal toxicity in the lobaplatin group was significantly lower than that in the cisplatin group (grade 3–4: 1.8% vs. 54.3%, p = 0.00), but the incidence of hematological toxicity in the lobaplatin group was significantly greater than that in the cisplatin group (grade 3–4: leukopenia, 55.2% vs. 30.6%, p = 0.007; thrombocytopenia: 44.8% vs. 1.6%, p = 0.00; neutropenia: 48.3% vs. 30.6%, p = 0.048). However, the dose of weekly lobaplatin combined with radiotherapy was significantly greater than the MTD observed in our study. Therefore, in Tian’s study, ruling out the possibility that lobaplatin overdose resulted in the high hematological toxicity observed in the lobaplatin group was difficult. Unlike in previous phase I studies of lobaplatin [16, 17, 22], no severe thrombocytopenia was observed in our study, most likely due to the varied administration methods implemented in the studies. In Gietema's [16], Fiebig's [17], and Peng's [22] studies, lobaplatin was administered through 72-h continuous infusion daily for five days every four weeks and in combination with docetaxel every three weeks. In our study, we administered lobaplatin weekly with concurrent radiotherapy using the VMAT technique, and toxicities were found as follows: four patients (one at level 4 and three at level 5) and two patients (one at level 4 and one at level 5) with grade 1 and 2 thrombocytopenia, respectively. Instead, fatigue was the dose limiting nonhematologic toxicity in this cohort, representing a previously unreported observation. Furthermore, we found fatigue to be an important treatment adverse event that could be easily underestimated, most likely due to patients' high acceptance and inaccurate assessment of this adverse effect. This toxicity substantially impairs quality of life, particularly role functioning and global health, supporting the need for more comprehensive assessment of the general condition of patients who are treated with concurrent lobaplatin is needed. The study has several limitations. First, as a Phase I trial, this study was not designed with the statistical power to evaluate treatment efficacy. Second, all enrolled patients were of Han Chinese ethnicity, which limits the generalizability of the findings to other ethnic populations and warrants further investigation. Third, the absence of a control group with cisplatin or other chemotherapeutic agents precludes direct comparisons of toxicity or efficacy. Based on the MTD established in this trial, we are currently planning a multi-center Phase II study. Conclusions Based on our findings, the MTD of weekly lobaplatin in patients receiving concurrent chemoradiotherapy for LACC was 14 mg/m2. Considering the hematologic and nonhematologic toxicities, we recommend a weekly dose of 12 mg/m2 of lobaplatin when combined with radiotherapy in patients with LACC. A phase II clinical study is being planned to confirm the efficacy and toxicity of this regimen. Supplementary Information Supplementary Material 1. Supplementary Material 1.